Therapy Areas: Oncology
VieCure Partners with Clarified Precision Medicine to Accelerate the Adoption of Precision Oncology
12 August 2022 - - US-based cancer care company VieCure has forged a new strategic collaboration with US-based precision oncology program developer Clarified Precision Medicine which to make precision oncology more accessible for patients and community oncologists, the company said.

In recent years there has been a large shift towards the use of cancer treatments which respond specifically to the molecular profile of the cancer (e.g., genomic data).

These data are complex, considerable, and difficult to access at the community oncology level.

This has highlighted a critical absence of medical guidance for both providers and payors and has motivated VieCure and Clarified Precision Medicine to work together to provide oncologists and their patients with clear, usable interpretations of any commercial comprehensive molecular profiling test along with a ranked list of treatment options which are reviewed by nationally recognized precision oncology experts.

This partnership will also facilitate objective, third-party clinical review to assist a payor with prior authorization or an approval decision.

VieCure said it will fully integrate the Clarified Precision Medicine Somatic and Germline Clinical Consultation process within its A.I. platform and offer community oncologists with streamlined access to Clarified's nationally recognized test interpretation team.

These professionals will function as elastic supply for the clinical providers on the ground who are working tirelessly everyday to help cancer patients and offer them with the best patient specific options possible.

Clarified Precision Medicine has also developed additional tools which help providers manage toxicities, optimize supportive care, and improve overall clinical efficiency.

VieCure will integrate the Clarified Medicine Precision testing tools within its platform and make the Clarified offering available to oncologists and clinical users later this year.

Oncologists using the VieCure platform will be able to order their molecular test (eg. next generation tumor sequencing) directly out of the VieCure platform and then obtain their precision medicine review within 48 hours, the company said.

VieCure has developed a proprietary artificial intelligence informatics software platform in conjunction with a clinical inference engine and point of care decision support system in oncology.

The Clarified Precision Medicine team is a collection of experienced practicing precision medicine clinicians.

Clarified Precision Medicine is composed of talent in Medical Oncology, Oncology Pharmacy, Data Integration, Molecular Pathology with over 85 years in the application of Precision Oncology.

The founders have built precision oncology programs in university, community, and integrated health systems. Clarified Precision Medicine offers expert clinical somatic and germline consultations through its Clarified Select and OncoGuardian solutions.